Most Read Articles
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

10 Jun 2018
Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
10 Jun 2018
The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Novel cisplatin nanoparticle safe as adjunctive treatment for solid tumours

11 Jan 2018

Use of NC-6004, a novel cisplatin nanoparticle developed using micellar technology, as an adjunct to gemcitabine in the treatment of patients with advanced solid tumours appears to be well tolerated, and greater equivalent doses of cisplatin are achieved with no clinically significant neurotoxicity, ototoxicity or nephrotoxicity, as shown in a recent study.

A total of 22 patients with advanced solid tumours were given NC-6004 at 60–180 mg/m2 on day 1 and gemcitabine at 1,250 mg/m2 on days 1 and 8 every 3 weeks. Dose escalation of NC-6004 was initiated with a single patient run-in until a dose-limiting toxicity occurred at 180 mg/m2.

There were four cohorts of four patients enrolled at doses predicted by the Bayesian continual reassessment model (N-CRM). Maximum tolerated dose (MTD) was defined as having the greatest probability of target toxicity <25 percent. Quality of life was evaluated using the EORTC-QLQ-C30.

The most commonly reported grade III/IV haematologic adverse events were leukopaenia (68 percent) and thrombocytopaenia (59 percent). Of the 20 pretreated patients evaluable for response, 10 had previous exposure to a platinum agent. The MTD was 135 mg/m2.

A total of nine patients were treated at MTD, with treatment lasting a median of 15 weeks (range, 3–50). There were 11 patients (55 percent) who showed tumour shrinkage, three patients (15 percent) who had partial responses, and 14 patients (70 percent) who achieved stable disease.

EORTC QLC-C30 scores improved or remained stable in most patients.

The present data demonstrate the tolerability and promising activity of NC-6004 in combination with gemcitabine, researchers said, adding that the combination warrants further investigation in phase II trials enrolling nonsmall cell lung cancer, biliary tract and bladder cancer patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

10 Jun 2018
Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
10 Jun 2018
The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.